Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

Type of payment of licensing agreements

  • Upfront payments
  • Milestone payments
  • Type of protein degrader
  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders
  • Therapeutic area
  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

Route of administration  

Oral

Intravenous

Other routes

Key geographical region

North America

Europe

Asia-Pacific

 

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Arvinas
  • Captor Therapeutics
  • Celgene
  • Genetech
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health 
  • Sanofi Genzyme
  • Zenopharm

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Company Profiles

6. Clinical Trial Analysis

7. KOL Analysis 

8. Publication Analysis

9. Funding and Investment Analysis 

10. Partnerships and Collaborations 

11.  Market Sizing and Opportunity Analysis

12. Executive Insights

13. Concluding Remarks

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe